Oric Pharmaceuticals, Inc. SEC Filings

ORIC Pharmaceuticals filed its Q3 2025 10-Q, reporting a net loss of $32.6 million for the quarter and $99.0 million for the nine months ended September 30, 2025. Operating expenses were $36.7 million in Q3, driven by research and development of $28.8 million and general and administrative of $7.9 million.

Liquidity strengthened: cash, cash equivalents and investments were $413.0 million as of September 30, 2025, supported by financing. During Q3 2025, the company raised $108.7 million net via its ATM through the sale of 10,930,032 shares at a weighted average price of $10.10. In May 2025, it completed a private placement for $125.0 million gross, including pre-funded warrants. Management believes current resources fund the plan into the second half of 2028.

ORIC announced a strategic pipeline prioritization on August 12, 2025, focusing on ORIC-944 and enozertinib, with an approximately 20% workforce reduction and a one-time charge of about $1.9 million. As of November 5, 2025, shares outstanding were 97,389,279. The company highlighted ORIC-944 dose optimization progress and expects an enozertinib data update in the fourth quarter of 2025.

ORIC Pharmaceuticals furnished an update on its financials by issuing a press release covering results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.

The information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference into other filings unless specifically referenced. The report was signed by Dominic Piscitelli, Chief Financial Officer.

Oric Pharmaceuticals insider transactions by CFO Dominic Piscitelli show a simultaneous option exercise and sale on 10/06/2025. The filing reports exercise of 11,000 stock options at an exercise price of $4.36 per share, resulting in immediate acquisition of 11,000 common shares. Those 11,000 shares were sold under a Rule 10b5-1 plan at a weighted average price of $14.5199 per share, completing sales in the $14.50–$14.53 range and leaving the reporting person with 48,317 shares outstanding directly. After the transactions, the reporting person holds 196,500 shares subject to outstanding options. The sale was executed pursuant to a trading plan adopted on 06/24/2025.

Oric Pharmaceuticals director and CEO Chacko Jacob reported the sale of 37,461 shares of ORIC common stock on 10/06/2025. The filing shows the shares were sold under a Rule 10b5-1 trading plan adopted on 06/21/2025 at a weighted average price of $12.32 (range $12.07–$12.59). After the reported sale, the reporting person beneficially owned 531,419 shares directly; the filing separately discloses 178,667 RSUs and 3,378,000 stock options previously reported on Table II and not included in that total. The Form 4 was signed by an attorney-in-fact on 10/08/2025.

Oric Pharmaceuticals, Inc. filed a Form 144 reporting a proposed sale of 50,000 common shares through J.P. Morgan Securities LLC on 10/06/2025. The filing lists an aggregate market value of $725,000 and shows 97,122,987 shares outstanding, indicating the block represents a small fraction of total outstanding stock. The securities were acquired the same day via a stock option exercise and payment was made in cash. No sales by the same person were reported in the prior three months. The filer certifies they are not aware of undisclosed material adverse information and includes the standard signature attestation under penalty of law.

Chacko Jacob, President and CEO and a director of Oric Pharmaceuticals, sold 125,000 shares of the company's common stock on September 22, 2025 under a Rule 10b5-1 trading plan. The reported weighted average price for the aggregate sale was $10.7995, with the shares sold in a range of $10.57 to $10.92. After the sale, the reporting person beneficially owned 656,419 shares of common stock directly. The filing also discloses outstanding equity awards not included in that total: 178,667 RSUs and stock options to purchase 3,378,000 shares, which were previously reported on Table II.

Oric Pharmaceuticals, Inc. notice reports a proposed sale of 250,000 common shares through J.P. Morgan Securities LLC on 09/22/2025 with an aggregate market value of $2,625,000. The issuer has 97,122,987 shares outstanding, making the offered amount a small fraction of total shares. The filer states the 250,000 shares were acquired in an open market purchase on 05/11/2022 and were paid for in cash. The filing reports no securities sold in the past three months and includes the seller's certification regarding absence of undisclosed material adverse information.

Viking Global and affiliated entities report a passive 9.99% position in Oric Pharmaceuticals (ORIC). The Schedule 13G/A shows Viking Global Investors LP and related funds and entities collectively beneficially own 8,729,345 shares of Oric common stock on a fully reported basis, equal to 9.99% of 85,224,191 shares outstanding (May 29, 2025 basis). Holdings arise from directly owned common stock plus pre-funded warrants exercisable for additional shares, but exercise is limited by a contractual "Blocker" that caps beneficial ownership at 9.99% (adjustable up to 19.99% with notice). Ownership is held through VGOP and VGOD (detailed share and warrant counts provided), VGI provides managerial services and has shared voting/dispositive authority, and three named executives are disclosed as having shared authority. The filing certifies the stake is not intended to influence control.

ORIC Pharmaceuticals Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,162,637 shares of ORIC common stock, representing 8.4% of the outstanding class based on 85,225,191 shares. Nextech Crossover I GP S.a. r.l. is the general partner of Nextech Crossover I SCSp and Nextech principals Ian Charoub, Costas Constantinides and Rocco Sgobbo have voting and dispositive power over the shares. The filing states the position is not held to influence control of the issuer.